{"id":4702,"date":"2026-05-19T08:42:47","date_gmt":"2026-05-19T08:42:47","guid":{"rendered":"https:\/\/news.gmj.ge\/?p=4702"},"modified":"2026-05-19T08:42:47","modified_gmt":"2026-05-19T08:42:47","slug":"alternating-hemiplegia-childhood-rare-neurological-disorder","status":"publish","type":"post","link":"https:\/\/news.gmj.ge\/?p=4702","title":{"rendered":"Alternating Hemiplegia of Childhood: Decoding a Rare Neurological Disorder"},"content":{"rendered":"

Alternating hemiplegia of childhood (AHC) is a rare neurological disorder characterized by episodes of temporary paralysis affecting one side of the body, often accompanied by involuntary eye movements and developmental delays. According to research published in PubMed Central<\/a>, AHC typically manifests in infants and young children, presenting diagnostic and therapeutic challenges for clinicians across paediatric neurology.<\/p>\n

\n
Before age 18 months<\/div>\n
Typical age of onset for alternating hemiplegia of childhood episodes in affected individuals<\/div>\n<\/div>\n

A Genetic Foundation Emerges<\/h2>\n

Recent advances in genetic sequencing have revolutionized understanding of AHC. Mutations in the ATP1A3 gene, which encodes a sodium-potassium pump protein essential for neuronal function, account for the majority of AHC cases. Research from Nature Medicine<\/a> has demonstrated that these mutations disrupt the normal function of brain cells, leading to the episodic paralysis characteristic of the disorder.<\/p>\n

The ATP1A3 gene functions as a critical regulator of ion balance across cell membranes. When mutated, this imbalance triggers the abnormal neural activity that produces AHC symptoms. Clinicians now recognize that genetic testing has become essential for confirming diagnosis and enabling families to understand the inherited nature of the condition.<\/p>\n

Clinical Presentation and Diagnostic Challenges<\/h2>\n

AHC manifests through episodic hemiplegia\u2014temporary one-sided weakness or paralysis\u2014that can alternate between sides of the body. Episodes typically last hours to days and may be triggered by stress, illness, or fatigue. According to data from The New England Journal of Medicine<\/a>, affected children often experience nystagmus (involuntary eye movements) and developmental regression, which can significantly impact cognitive and motor milestones.<\/p>\n

Diagnosis remains challenging because episodes are often intermittent and imaging studies such as magnetic resonance imaging (MRI) typically appear normal between attacks. This has historically led to misdiagnosis or delayed recognition, with some children incorrectly diagnosed with epilepsy or conversion disorder. Early genetic testing is now recognised as the gold standard for confirmation and can spare families from prolonged diagnostic odysseys.<\/p>\n

Paediatric neurologists at National Institutes of Health<\/a>-affiliated centres emphasise that a detailed history of symptom timing, laterality, and associated features\u2014combined with ATP1A3 genetic sequencing\u2014provides the most reliable diagnostic pathway.<\/p>\n

Treatment Strategies and Clinical Management<\/h2>\n

Currently, no cure exists for AHC, but several pharmacological agents have demonstrated efficacy in reducing episode frequency and severity. Flunarizine, a calcium channel blocker, has become a first-line therapy in many centres, with clinical trials showing meaningful reduction in attack burden. Supportive care\u2014including physiotherapy, educational support, and family counselling\u2014remains cornerstone management.<\/p>\n

Research published in The Lancet<\/a> indicates that early intervention with appropriate medications, combined with aggressive management of triggers, can substantially improve quality of life for affected children and reduce long-term neurological complications. Recent interest in targeted therapies directed at ATP1A3 dysfunction represents a promising frontier for future treatment development.<\/p>\n

\n

Mutations in the ATP1A3 gene account for approximately 70\u201380% of confirmed alternating hemiplegia of childhood cases, and genetic testing now enables accurate diagnosis and family counselling.<\/p>\n

\u2014 Researchers at National Institutes of Health<\/a> (Nature Medicine, 2024)<\/cite><\/p><\/blockquote>\n

\n

Key Clinical Features of Alternating Hemiplegia of Childhood<\/h4>\n
\n
\n
Typical Onset<\/div>\n
18 months or earlier<\/div>\n
Episodes begin in infancy; some present in neonatal period<\/div>\n<\/div>\n
\n
Diagnostic Confirmation<\/div>\n
ATP1A3 genetic testing<\/div>\n
Gold standard; imaging usually normal between episodes<\/div>\n<\/div>\n<\/div>\n

Source: National Institutes of Health, Nature Medicine (2024) | Georgian Medical Journal News<\/p>\n<\/div>\n

\n

Key takeaways<\/h3>\n